Boston Trust Walden Corp Has $59.46 Million Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Boston Trust Walden Corp cut its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 0.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 326,302 shares of the medical instruments supplier’s stock after selling 1,228 shares during the quarter. Boston Trust Walden Corp owned 1.34% of ICU Medical worth $59,459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of ICU Medical by 14.8% during the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after acquiring an additional 315,103 shares in the last quarter. Silvercrest Asset Management Group LLC raised its holdings in ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after buying an additional 145,485 shares during the last quarter. Mesirow Institutional Investment Management Inc. bought a new position in shares of ICU Medical in the first quarter valued at $15,425,000. Victory Capital Management Inc. grew its holdings in shares of ICU Medical by 2,966.3% during the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after buying an additional 137,222 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of ICU Medical by 327.8% during the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock worth $16,158,000 after acquiring an additional 104,264 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Performance

NASDAQ:ICUI traded up $0.08 during trading on Friday, reaching $175.56. The company’s stock had a trading volume of 138,099 shares, compared to its average volume of 248,863. ICU Medical, Inc. has a 12 month low of $78.28 and a 12 month high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The firm has a 50 day moving average of $172.59 and a 200-day moving average of $134.67.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. Equities analysts forecast that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

Analyst Ratings Changes

ICUI has been the topic of several recent research reports. Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. KeyCorp lifted their target price on ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on shares of ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.25.

Insiders Place Their Bets

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock valued at $6,679,322 over the last ninety days. 6.70% of the stock is currently owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.